SEC Filing Summary: Neuralstem, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuralstem, Inc. on June 5, 2009, covering an event that occurred on June 4, 2009. The company is a Delaware corporation headquartered in Rockville, Maryland, focused on neuroregenerative therapies.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding intellectual property and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes
The material event reported is the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for Patent Application No. 12/049,922. The patent is entitled "Use of Fused Nicotinamides to Promote Neurogenesis."
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary beyond the announcement of the patent allowance. No specific risks or contingencies are detailed in this report, though the document includes standard disclaimers stating that the information is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the status and scope of Patent Application 12/049,922 regarding "Use of Fused Nicotinamides to Promote Neurogenesis."
- Confirm the issuance date of the press release (June 4, 2009) referenced as Exhibit 99.1.
- Note that this filing does not provide updated financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.